Get started
Author

Alejandro García‐Álvarez

Observed names: A. Garcia-Alvarez, A. García-Alvarez, A. García-Álvarez, Alejando García-Álvarez, Alejandro Garcia-Alvarez, Alejandro García Alvarez, Alejandro García-Alvarez, Alejandro García-Álvarez
ORCID: 0000-0001-6948-0485
Observed ORCID: 0000-0001-6948-0485
OpenAlex ID: A5007436184
Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies
2021 · Alejandro Garcia-Alvarez, Andri Papakonstantinou, et al. · Cancers · 110
PDF
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
2023 · J. Capdevila, J. Hernando, et al. · Nature Communications · 60
PDF
What is the status of immunotherapy in thyroid neoplasms?
2022 · Alejandro Garcia-Alvarez, Jorge Hernando, et al. · Frontiers in Endocrinology · 49
PDF
Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma
2021 · Alejandro Garcia-Alvarez, Carolina Ortiz, et al. · OncoTargets and Therapy · 45
PDF
A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer
2025 · Maria Balaguer-Montero, Adrià Marcos Morales, et al. · Cell Reports Medicine · 33
Treatment outcomes of advanced digestive well-differentiated grade 3 NETs
2021 · Louis de Mestier, Angela Lamarca, et al. · Endocrine Related Cancer · 33
PDF
Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients
2020 · A. Hernando-Calvo, A. García-Alvarez, et al. · Clinical & Translational Oncology · 21
A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
2025 · Jaume Capdevila, Virginia Pubul, et al. · BMC Cancer · 14
PDF
Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study
2025 · Maribel del Olmo-García, Lorena Hernandez-Rienda, et al. · The Oncologist · 12
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
2023 · Jorge Hernando, Maria Roca-Herrera, et al. · European Journal of Cancer · 12
PDF
DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype
2023 · Estefania Cuesta-Borràs, Cándida Salvans, et al. · Cell Reports · 10
PDF
Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report
2021 · Oriol Mirallas, Francesca Filippi-Arriaga, et al. · Frontiers in Endocrinology · 10
Drug Development in Neuroendocrine Tumors: What Is on the Horizon?
2021 · Alejandro Garcia-Alvarez, Jorge Hernando Cubero, et al. · Current Treatment Options in Oncology · 10
Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)
2025 · Jaume Capdevila, Jorge Hernando, et al. · Clinical Cancer Research · 8
What Is the Status of Immunotherapy in Neuroendocrine Neoplasms?
2022 · Alejandro Garcia-Alvarez, Jorge Hernando Cubero, et al. · Current Oncology Reports · 8
Genomics Review of Selective RET Inhibitors Sensitivity in Thyroid Cancer Clinical Trials
2025 · Sara Gil‐Bernabé, Lucía García‐DeLaFuente, et al. · American Journal of Medical Genetics Part C Seminars in Medical Genetics · 6
PDF
Phase II study of durvalumab plus total neoadjuvant therapy (TNT) in locally advanced rectal cancer: The GEMCAD-1703 DUREC trial.
2020 · Jaume Capdevila, Ismael Macias Declara, et al. · Journal of Clinical Oncology · 6
Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review
2024 · Natalia Soledad Tissera, Francesca Balconi, et al. · Cancer Treatment Reviews · 5
PDF
177Lu-edotreotide versus everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin: The phase 3 randomized LEVEL, GETNE-T2217 trial.
2024 · Alejandro Garcia-Alvarez, Rocio Garcia-Carbonero, et al. · Journal of Clinical Oncology · 3
PDF
Cabozantinib plus atezolizumab in patients with advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II trial (CABATEN / GETNE-T1914).
2024 · Jorge Hernando, Javier Molina-Cerrillo, et al. · Journal of Clinical Oncology · 3
Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial
2026 · Jaume Capdevila, Jorge Hernando, et al. · Nature Communications · 2
PDF
Larotrectinib in patients with tropomyosin receptor kinase fusion solid tumors in Spain (SPAINTRK)
2026 · Jorge Hernando, Carlos Lopez, et al. · European Journal of Cancer · 2
Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours: findings from the phase II TALENT trial
2023 · Marta Ligero, Jorge Hernando, et al. · BJC Reports · 2
PDF
Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.
2023 · Jaume Capdevila, Monica Guillot, et al. · Journal of Clinical Oncology · 2
1558P Pancreatic cancer (PC) in patients (pts) younger than 50 years: Clinical outcomes and actionable genomic/genetic alterations
2020 · A. Garcia-Alvarez, H. Verdaguer, et al. · Annals of Oncology · 2
Works count: 59
Citation count: 478
H-index: 10
I10-index: 13
Year
Topic
Type